Motley Fool Asset Management LLC Sells 6,661 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Motley Fool Asset Management LLC decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,443 shares of the biopharmaceutical company’s stock after selling 6,661 shares during the period. Motley Fool Asset Management LLC owned approximately 0.18% of Ultragenyx Pharmaceutical worth $7,146,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of RARE. Federated Hermes Inc. boosted its stake in Ultragenyx Pharmaceutical by 23.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,196,500 shares of the biopharmaceutical company’s stock worth $78,305,000 after purchasing an additional 419,900 shares in the last quarter. Hudson Bay Capital Management LP boosted its stake in Ultragenyx Pharmaceutical by 46.3% in the 3rd quarter. Hudson Bay Capital Management LP now owns 734,272 shares of the biopharmaceutical company’s stock worth $26,177,000 after purchasing an additional 232,500 shares in the last quarter. Vanguard Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 7,233,168 shares of the biopharmaceutical company’s stock worth $257,862,000 after purchasing an additional 214,666 shares in the last quarter. FMR LLC raised its position in Ultragenyx Pharmaceutical by 23.4% in the 3rd quarter. FMR LLC now owns 1,027,785 shares of the biopharmaceutical company’s stock worth $36,641,000 after buying an additional 195,108 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Ultragenyx Pharmaceutical by 23.8% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 748,278 shares of the biopharmaceutical company’s stock worth $26,676,000 after buying an additional 143,991 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE traded down $0.43 during mid-day trading on Thursday, reaching $43.85. 470,806 shares of the company traded hands, compared to its average volume of 758,706. The company’s 50 day moving average price is $47.94 and its 200-day moving average price is $43.75. The firm has a market cap of $3.61 billion, a PE ratio of -5.32 and a beta of 0.65. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The company had revenue of $127.39 million during the quarter, compared to the consensus estimate of $119.38 million. During the same period in the previous year, the company posted ($2.16) EPS. The firm’s revenue was up 23.3% on a year-over-year basis. On average, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Wedbush reissued a “neutral” rating and issued a $48.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, April 16th. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Robert W. Baird boosted their target price on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, April 5th. Finally, Canaccord Genuity Group upped their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $88.08.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the transaction, the executive vice president now directly owns 252,823 shares in the company, valued at approximately $12,623,452.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Matthew K. Fust sold 12,195 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the transaction, the director now directly owns 14,860 shares in the company, valued at approximately $756,076.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the transaction, the executive vice president now owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The disclosure for this sale can be found here. Insiders sold 32,116 shares of company stock worth $1,645,983 in the last three months. 6.80% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.